FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3197018837> ?p ?o ?g. }

• W3197018837 abstract "Objective: This study evaluated the effect of fremanezumab on health-related quality of life (HRQoL) using the Migraine-Specific Quality of Life (MSQoL) questionnaire in patients with chronic migraine (CM) who received concomitant preventive migraine medication. Background: CM is characterized by frequent attacks, which adversely affect HRQoL. Fremanezumab, a fully humanized monoclonal antibody (IgG2Δa) that selectively targets calcitonin gene-related peptide (CGRP), is approved by the US Food and Drug Administration for the preventive treatment of CM. Design/Methods: In this phase 3, multicenter, randomized, double-blind, parallel-group study, patients with CM were randomized 1:1:1 to receive subcutaneous fremanezumab quarterly (675 mg at baseline, placebo at Weeks 4 and 8), fremanezumab monthly (675 mg at baseline, 225 mg at Weeks 4 and 8), or placebo (at baseline, Weeks 4 and 8). A subset of patients was allowed use of one preventive migraine medication if the dosing was stable ≥2 months before the pre-treatment period. The MSQoL questionnaire (version 2.1) assessed the role function-restrictive (RR), role function-preventive (RP), and emotional function (EF) domains (range 0–100; higher scores indicate better HRQoL). MSQoL domains were analyzed using an analysis of covariance model. Results: A total of 239/1121 patients with CM (fremanezumab quarterly: n=77; fremanezumab monthly: n=85; placebo: n=77) received concomitant preventive migraine treatment and were included in this analysis. Fremanezumab treatment showed greater improvements from baseline in MSQoL RR domain scores (quarterly [least-squares mean]: 22.6, P=0.0259; monthly: 24.0, P=0.0048) compared with placebo (15.9) during the 12-week treatment period. Monthly fremanezumab treatment showed greater improvements from baseline in MSQoL RP domain scores (quarterly: 17.6, P=0.1467; monthly: 19.1, P=0.0337) compared with placebo (13.7) during the 12-week treatment period. Fremanezumab treatment did not have a significant effect on MSQoL EF domain scores. Conclusions: Fremanezumab improves some MSQoL domain scores in patients with CM who are using a concomitant preventive medication. Disclosure: Dr. Gandhi has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Teva Pharmaceuticals.. Dr. Lipton has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with American Academy of Neurology, Alder Biopharmaceuticals, Allergan, American Headache Society, Amgen, Autonomic Technologies, Avanir Pharmaceuticals, Biohaven, Biovision, Boston Scientific, Dr. Reddy’s, Electrocore, Eli Lilly, eNeura Therapeutics, GlaxoSmithKline, Merck, Pernix, Pfizer, Supernus, Teva, Trigemina, Vector, and Vedanta. Dr. Lipton holds stock and/or stock options in Biohaven. Dr. Cohen has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Employee of Teva Pharmaceuticals." @default.
• W3197018837 created "2021-09-13" @default.
• W3197018837 creator A5000448269 @default.
• W3197018837 creator A5026360523 @default.
• W3197018837 creator A5031700821 @default.
• W3197018837 date "2019-04-09" @default.
• W3197018837 modified "2023-09-24" @default.
• W3197018837 title "The Impact of Fremanezumab on Migraine-Specific Health-Related Quality of Life in Chronic Migraine Patients With Concomitant Preventive Medication Use (P1.10-012)" @default.
• W3197018837 hasPublicationYear "2019" @default.
• W3197018837 type Work @default.
• W3197018837 sameAs 3197018837 @default.
• W3197018837 citedByCount "0" @default.
• W3197018837 crossrefType "journal-article" @default.
• W3197018837 hasAuthorship W3197018837A5000448269 @default.
• W3197018837 hasAuthorship W3197018837A5026360523 @default.
• W3197018837 hasAuthorship W3197018837A5031700821 @default.
• W3197018837 hasConcept C118303440 @default.
• W3197018837 hasConcept C126322002 @default.
• W3197018837 hasConcept C142724271 @default.
• W3197018837 hasConcept C159110408 @default.
• W3197018837 hasConcept C163170386 @default.
• W3197018837 hasConcept C170493617 @default.
• W3197018837 hasConcept C1862650 @default.
• W3197018837 hasConcept C204787440 @default.
• W3197018837 hasConcept C27081682 @default.
• W3197018837 hasConcept C2777288759 @default.
• W3197018837 hasConcept C2778541695 @default.
• W3197018837 hasConcept C2779384505 @default.
• W3197018837 hasConcept C2779951463 @default.
• W3197018837 hasConcept C2910587157 @default.
• W3197018837 hasConcept C71924100 @default.
• W3197018837 hasConceptScore W3197018837C118303440 @default.
• W3197018837 hasConceptScore W3197018837C126322002 @default.
• W3197018837 hasConceptScore W3197018837C142724271 @default.
• W3197018837 hasConceptScore W3197018837C159110408 @default.
• W3197018837 hasConceptScore W3197018837C163170386 @default.
• W3197018837 hasConceptScore W3197018837C170493617 @default.
• W3197018837 hasConceptScore W3197018837C1862650 @default.
• W3197018837 hasConceptScore W3197018837C204787440 @default.
• W3197018837 hasConceptScore W3197018837C27081682 @default.
• W3197018837 hasConceptScore W3197018837C2777288759 @default.
• W3197018837 hasConceptScore W3197018837C2778541695 @default.
• W3197018837 hasConceptScore W3197018837C2779384505 @default.
• W3197018837 hasConceptScore W3197018837C2779951463 @default.
• W3197018837 hasConceptScore W3197018837C2910587157 @default.
• W3197018837 hasConceptScore W3197018837C71924100 @default.
• W3197018837 hasLocation W31970188371 @default.
• W3197018837 hasOpenAccess W3197018837 @default.
• W3197018837 hasPrimaryLocation W31970188371 @default.
• W3197018837 hasRelatedWork W1657838061 @default.
• W3197018837 hasRelatedWork W1670413084 @default.
• W3197018837 hasRelatedWork W2089055001 @default.
• W3197018837 hasRelatedWork W2123474211 @default.
• W3197018837 hasRelatedWork W2472696471 @default.
• W3197018837 hasRelatedWork W2777881032 @default.
• W3197018837 hasRelatedWork W2794514658 @default.
• W3197018837 hasRelatedWork W2805066472 @default.
• W3197018837 hasRelatedWork W2808055426 @default.
• W3197018837 hasRelatedWork W2809684180 @default.
• W3197018837 hasRelatedWork W2883358571 @default.
• W3197018837 hasRelatedWork W2888596619 @default.
• W3197018837 hasRelatedWork W2899506043 @default.
• W3197018837 hasRelatedWork W2921858277 @default.
• W3197018837 hasRelatedWork W2939449854 @default.
• W3197018837 hasRelatedWork W3014490536 @default.
• W3197018837 hasRelatedWork W3046802458 @default.
• W3197018837 hasRelatedWork W3085896652 @default.
• W3197018837 hasRelatedWork W3126954968 @default.
• W3197018837 hasRelatedWork W3159959646 @default.
• W3197018837 hasVolume "92" @default.
• W3197018837 isParatext "false" @default.
• W3197018837 isRetracted "false" @default.
• W3197018837 magId "3197018837" @default.
• W3197018837 workType "article" @default.